NCT05124600Recruiting
An Individualized-health eLibrary App for People With Multiple Sclerosis
An Individualized-health eLibrary App for People With Multiple Sclerosis: Testing Feasibility and Effectiveness of a Brief Education Intervention
Source: ClinicalTrials.gov · Last updated 24 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to assess the effectiveness after using a new individualized-health e-library app named SavvyHealth among people with multiple sclerosis.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 26 Oct 2021
- Start date
- 25 Oct 2021
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Diseases
- Multiple sclerosis
- NCT number
- NCT05124600
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 25 Oct 2021 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- diagnosed with MS;
- 18 years or older;
- one comorbidity evaluated by a validated comorbidity questionnaire for people with MS;
- willing to take a survey;
- willing to use the app for 21 days;
- willing to be assigned to either the intervention or control group.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Illinois Urbana-Champaign Coordinator of this site? Confirm its status | Champaign | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.